CGRP mAb Subcutaneous denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Issued a Duplicate-Therapy Denial for Your CGRP Monoclonal Antibody

Cigna's duplicate-therapy denial means the plan's automated review flagged that another drug in the same therapeutic class — most likely a different CGRP monoclonal antibody — is already active on your profile, or that a previously approved CGRP agent was dispensed within a defined look-back window. This is one of the most routinely overturned denial types because each CGRP monoclonal antibody has a distinct molecular target, injection schedule, and formulation, meaning they are not automatically interchangeable.

## Why This Denial Is Appealable

Your prescriber chose this specific agent for documented clinical reasons: prior response or non-response to another CGRP antibody, tolerability differences, administration preference affecting adherence, or an insurance gap that interrupted a previous course. Cigna's own coverage policy distinguishes between agents when a patient has an inadequate response to one. Document the distinction clearly and the denial often reverses on internal appeal.

## Your Federal Appeal Rights

Regardless of how your plan is structured, federal law protects your right to appeal:

• ERISA §503 (self-funded employer plans) requires a full-and-fair review with a decision on urgent matters within 72 hours and standard appeals within 60 days of your appeal submission.
• ACA §2719 gives you access to an Independent External Review if internal appeal is denied; the external-review window is generally open for approximately four months after final internal denial.
• Expedited review is available if your condition is urgent — ask your prescriber to flag this when submitting supporting documentation.

## Documentation to Gather

• Diagnosis confirmation: chart notes and ICD codes establishing your migraine diagnosis and frequency/severity classification.
• Prior CGRP agent history: name, dates dispensed, discontinuation reason (non-response, adverse effect, formulary removal, coverage lapse) — obtain the dispensing pharmacy printout.
• Clinical differentiation letter: a prescriber letter explaining why this specific CGRP antibody is medically necessary rather than resuming the previously covered agent.
• Insurer's coverage policy: download Cigna's current medical coverage policy for CGRP antagonists directly from cigna.com; note any language permitting a second CGRP agent after documented failure.

## Criteria-Mapping Structure

For each requirement listed in Cigna's published CGRP coverage policy, pair it with the exact chart fact that satisfies it. Example structure:

| Policy Requirement | Supporting Chart Evidence | |---|---| | Diagnosis of episodic or chronic migraine confirmed | Chart note date + ICD code | | Adequate trial of prior CGRP agent (dates, outcome) | Pharmacy record + visit note documenting outcome | | Clinical reason to switch agents | Prescriber letter paragraph citing tolerability or non-response |

Confirm the exact eligibility thresholds and switching criteria by reading Cigna's current policy document and the FDA-approved prescribing label for this agent. Your appeal letter should quote the policy language and answer it line by line with dated chart evidence.